Abstract
A series of phenyl alkyl ketone derivatives based phosphodiesterase 4 (PDE4) inhibitors was subjected to 2D Quantitative Structure–Activity Relationships (2D QSAR) and Hologram Quantitative Structure–Activity Relationship (HQSAR) studies. The dataset was divided into training and test sets by applying K-means clustering, and 2D QSAR models were established using stepwise linear regression analysis, replacement method and enhanced replacement methods. The models obtained demonstrated high correlation coefficient (R2=0.8374) and low standard deviation (S=0.4442). The robustness of models was confirmed using leave one out cross validation (R2 cv=0.7189), Y scrambling (R2=0.3640), and by test set prediction (R2 pred=0.6867). Topological, steric, electronic and electrotopological descriptors of phenyl alkyl ketone derivatives showed good correlation with the PDE4 inhibitory activity. HQSAR models were established using various fragment sizes, hologram lengths and fragment types. The top HQSAR model was justified by high R2 value of 0.973 and R2 cv value of 0.641. New molecules were designed based on these results and the activity was predicted using the established models.
Keywords: cAMP, cGMP, HQSAR, Phosphodiesterase, QSAR, Y scrambling.
Current Enzyme Inhibition
Title:Quantitative Structure Activity Relationship and Design of Phenyl Alkyl Ketone Derivatives as Inhibitors of Phosphodiesterase 4
Volume: 10 Issue: 1
Author(s): Anand Gaurav, Vertika Gautam and Ranjit Singh
Affiliation:
Keywords: cAMP, cGMP, HQSAR, Phosphodiesterase, QSAR, Y scrambling.
Abstract: A series of phenyl alkyl ketone derivatives based phosphodiesterase 4 (PDE4) inhibitors was subjected to 2D Quantitative Structure–Activity Relationships (2D QSAR) and Hologram Quantitative Structure–Activity Relationship (HQSAR) studies. The dataset was divided into training and test sets by applying K-means clustering, and 2D QSAR models were established using stepwise linear regression analysis, replacement method and enhanced replacement methods. The models obtained demonstrated high correlation coefficient (R2=0.8374) and low standard deviation (S=0.4442). The robustness of models was confirmed using leave one out cross validation (R2 cv=0.7189), Y scrambling (R2=0.3640), and by test set prediction (R2 pred=0.6867). Topological, steric, electronic and electrotopological descriptors of phenyl alkyl ketone derivatives showed good correlation with the PDE4 inhibitory activity. HQSAR models were established using various fragment sizes, hologram lengths and fragment types. The top HQSAR model was justified by high R2 value of 0.973 and R2 cv value of 0.641. New molecules were designed based on these results and the activity was predicted using the established models.
Export Options
About this article
Cite this article as:
Gaurav Anand, Gautam Vertika and Singh Ranjit, Quantitative Structure Activity Relationship and Design of Phenyl Alkyl Ketone Derivatives as Inhibitors of Phosphodiesterase 4, Current Enzyme Inhibition 2014; 10 (1) . https://dx.doi.org/10.2174/15734080113096660006
DOI https://dx.doi.org/10.2174/15734080113096660006 |
Print ISSN 1573-4080 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6662 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Preparation, Crystallization and Preliminary X-Ray Analysis of the Fab Fragment of Monoclonal Antibody MN423, Revealing the Structural Aspects of Alzheimers Paired Helical Filaments
Protein & Peptide Letters Cell-Based Therapy to Promote Angiogenesis in the Brain Following Ischemic Damage
Current Vascular Pharmacology The NGF Metabolic Pathway in the CNS and its Dysregulation in Down Syndrome and Alzheimer’s Disease
Current Alzheimer Research Antidepressant Use in Children and Adolescents Diagnosed with Major Depressive Disorder: What Can We Learn from Published Data?
Reviews on Recent Clinical Trials Clinical Perspectives on Antidepressant Drug Development: A Critical Discussion
Current Pharmaceutical Design Dietary Interventions in Children with Autism Spectrum Disorders - An Updated Review of the Research Evidence
Current Clinical Pharmacology Frailty among HIV-1 Infected Adults under Antiretroviral Therapy in Indonesia
Current HIV Research Cariprazine in Bipolar Depression and Mania: State of the Art
CNS & Neurological Disorders - Drug Targets The Role of a Disturbed Arginine/NO Metabolism in the Onset of Cancer Cachexia: A Working Hypothesis
Current Medicinal Chemistry Multi-Target Drug Design of Anti-Alzheimer’s Disease based on Tacrine
Mini-Reviews in Medicinal Chemistry Editorial (Hot Topic :Treatment with Antidepressants)
Current Pharmaceutical Design Editorial (How Natural is it for Nature to Help with Major Depressive Disorder?)
CNS & Neurological Disorders - Drug Targets Interactions of Sex Steroids with Mechanisms of Inflammation
Current Drug Targets - Inflammation & Allergy Cigarette Smoke-Induced Proteostasis Imbalance in Obstructive Lung Diseases
Current Molecular Medicine Medicinal Agents and Metabolic Syndrome
Current Medicinal Chemistry Is Mental Practice an Effective Adjunct Therapeutic Strategy for Upper Limb Motor Restoration After Stroke? A Systematic Review and Meta- Analysis
CNS & Neurological Disorders - Drug Targets Protection Mechanisms Against Aβ42 Aggregation
Current Alzheimer Research Insight into the Structural Requirements of Narlaprevir-Type Inhibitors of NS3/NS4A Protease Based on HQSAR and Molecular Field Analyses
Combinatorial Chemistry & High Throughput Screening Assessment of Cardiac Performance with Magnetic Resonance Imaging
Current Cardiology Reviews The Putative Impact of Metabolic Health on Default Mode Network Activity and Functional Connectivity in Neuropsychiatric Disorders
CNS & Neurological Disorders - Drug Targets